Welcome to LookChem.com Sign In|Join Free

CAS

  • or

3068-34-6

Post Buying Request

3068-34-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • Featured products 2-Deoxy-2-acetaMido-3,4,6-tri-O-acetyl-α-D-glucopyranosyl chloride

    Cas No: 3068-34-6

  • No Data

  • 100 Gram

  • 1-10 Metric Ton/Month

  • Chemlyte Solutions
  • Contact Supplier

3068-34-6 Usage

Description

2-ACETAMIDO-2-DEOXY-ALPHA-D-GLUCOPYRANOSYL CHLORIDE 3,4,6-TRIACETATE, also known as Chloro 2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-α-D-glucopyranose (CAS# 3068-34-6), is a white solid with significant chemical properties. It is a key reactant in the total synthesis of glycosylated human interferon-γ, a type of protein with antiviral, antiproliferative, and immunomodulatory functions.

Uses

Used in Pharmaceutical Industry:
2-ACETAMIDO-2-DEOXY-ALPHA-D-GLUCOPYRANOSYL CHLORIDE 3,4,6-TRIACETATE is used as a reactant for the total synthesis of glycosylated human interferon-γ. This application is crucial because it helps in the development of therapeutic agents with enhanced antiviral, antiproliferative, and immunomodulatory properties. The glycosylation process improves the stability, solubility, and efficacy of the interferon-γ, making it a valuable component in the pharmaceutical industry for treating various diseases and conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 3068-34-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,0,6 and 8 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 3068-34:
(6*3)+(5*0)+(4*6)+(3*8)+(2*3)+(1*4)=76
76 % 10 = 6
So 3068-34-6 is a valid CAS Registry Number.
InChI:InChI=1/C14H20ClNO8/c1-6(17)16-11-13(23-9(4)20)12(22-8(3)19)10(24-14(11)15)5-21-7(2)18/h10-14H,5H2,1-4H3,(H,16,17)

3068-34-6 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (A1416)  2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl Chloride  >93.0%(T)

  • 3068-34-6

  • 1g

  • 470.00CNY

  • Detail
  • TCI America

  • (A1416)  2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl Chloride  >93.0%(T)

  • 3068-34-6

  • 5g

  • 1,460.00CNY

  • Detail

3068-34-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-ACETAMIDO-2-DEOXY-α-D-GLUCOPYRANOSYL CHLORIDE 3,4,6-TRIACETATE

1.2 Other means of identification

Product number -
Other names 1-Chloro-2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-α-D-glucose

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:3068-34-6 SDS

3068-34-6Relevant articles and documents

Genetically Introducing Biochemically Reactive Amino Acids Dehydroalanine and Dehydrobutyrine in Proteins

Yang, Bing,Wang, Nanxi,Schnier, Paul D.,Zheng, Feng,Zhu, He,Polizzi, Nicholas F.,Ittuveetil, Avinash,Saikam, Varma,Degrado, William F.,Wang, Qian,Wang, Peng G.,Wang, Lei

, p. 7698 - 7703 (2019)

Expansion of the genetic code with unnatural amino acids (Uaas) has significantly increased the chemical space available to proteins for exploitation. Due to the inherent limitation of translational machinery and the required compatibility with biological settings, function groups introduced via Uaas to date are restricted to chemically inert, bioorthogonal, or latent bioreactive groups. To break this barrier, here we report a new strategy enabling the specific incorporation of biochemically reactive amino acids into proteins. A latent bioreactive amino acid is genetically encoded at a position proximal to the target natural amino acid; they react via proximity-enabled reactivity, selectively converting the latter into a reactive residue in situ. Using this Genetically Encoded Chemical COnversion (GECCO) strategy and harnessing the sulfur-fluoride exchange (SuFEx) reaction between fluorosulfate-l-tyrosine and serine or threonine, we site-specifically generated the reactive dehydroalanine and dehydrobutyrine into proteins. GECCO works both inter- and intramolecularly, and is compatible with various proteins. We further labeled the resultant dehydroalanine-containing protein with thiol-saccharide to generate glycoprotein mimetics. GECCO represents a new solution for selectively introducing biochemically reactive amino acids into proteins and is expected to open new avenues for exploiting chemistry in live systems for biological research and engineering.

-

Pravdic et al.

, p. 302,305,306 (1975)

-

Synthesis of Asparagine Derivatives Harboring a Lewis X Type DC-SIGN Ligand and Evaluation of their Impact on Immunomodulation in Multiple Sclerosis

Doelman, Ward,Marqvorsen, Mikkel H. S.,Chiodo, Fabrizio,Bruijns, Sven C. M.,van der Marel, Gijsbert A.,van Kooyk, Yvette,van Kasteren, Sander I.,Araman, Can

supporting information, p. 2742 - 2752 (2020/12/29)

The protein myelin oligodendrocyte glycoprotein (MOG) is a key component of myelin and an autoantigen in the disease multiple sclerosis (MS). Post-translational N-glycosylation of Asn31 of MOG seems to play a key role in modulating the immune response towards myelin. This is mediated by the interaction of Lewis-type glycan structures in the N-glycan of MOG with the DC-SIGN receptor on dendritic cells (DCs). Here, we report the synthesis of an unnatural Lewis X (LeX)-containing Fmoc-SPPS-compatible asparagine building block (SPPS=solid-phase peptide synthesis), as well as asparagine building blocks containing two LeX-derived oligosaccharides: LacNAc and Fucα1-3GlcNAc. These building blocks were used for the glycosylation of the immunodominant portion of MOG (MOG31-55) and analyzed with respect to their ability to bind to DC-SIGN in different biological setups, as well as their ability to inhibit the citrullination-induced aggregation of MOG31-55. Finally, a cytokine secretion assay was carried out on human monocyte-derived DCs, which showed the ability of the neoglycopeptide decorated with a single LeX to alter the balance of pro- and anti-inflammatory cytokines, inducing a tolerogenic response.

Bisubstrate Ether-Linked Uridine-Peptide Conjugates as O-GlcNAc Transferase Inhibitors

Makwana, Vivek,Ryan, Philip,Malde, Alpeshkumar K.,Anoopkumar-Dukie, Shailendra,Rudrawar, Santosh

supporting information, p. 477 - 483 (2020/10/26)

The O-linked β-N-acetylglucosamine (O-GlcNAc) transferase (OGT) is a master regulator of installing O-GlcNAc onto serine or threonine residues on a multitude of target proteins. Numerous nuclear and cytosolic proteins of varying functional classes, including translational factors, transcription factors, signaling proteins, and kinases are OGT substrates. Aberrant O-GlcNAcylation of proteins is implicated in signaling in metabolic diseases such as diabetes and cancer. Selective and potent OGT inhibitors are valuable tools to study the role of OGT in modulating a wide range of effects on cellular functions. We report linear bisubstrate ether-linked uridine-peptide conjugates as OGT inhibitors with micromolar affinity. In vitro evaluation of the compounds revealed the importance of donor substrate, linker and acceptor substrate in the rational design of bisubstrate analogue inhibitors. Molecular dynamics simulations shed light on the binding of this novel class of inhibitors and rationalized the effect of amino acid truncation of acceptor peptide on OGT inhibition.

ANTIFUNGAL PRODRUGS

-

Page/Page column 6; 27; 28, (2021/12/08)

The invention relates to an antifungal prodrug which comprises an antifungal moiety which is linked to a trigger moiety by means of a self-immolative spacer. The trigger moiety is selected from glycosyl residues and oligosaccharides, stabilizes the self-immolative spacer and is cleavable by a pathogen hydrolytic enzyme which is preferably an extracellular glycosidase (EC 3.2.1). When the trigger moiety is cleaved by the pathogen hydrolytic enzyme, the self-immolative spacer undergoes a spontaneous degradation so as to release the antifungal moiety. The invention also relates to pharmaceutical compositions comprising said prodrug and to its use in the treatment of infectious diseases.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 3068-34-6